Мигрень у женщин в перименопаузальном периоде

Половые гормоны оказывают существенное влияние на течение мигрени у женщин. Период перименопаузы сопровождается нестабильной продолжительностью цикла, вазомоторными, урогенитальными и другими симптомами, при этом течение мигрени, как правило, усугубляется. В постменопаузе угасает фолликулярная функция яичников, течение мигрени в большинстве случаев улучшается. Однако в ходе ряда исследований было показано, что течение мигрени после менопаузы не меняется либо усугубляется. Также пациентки с мигренью в перименопаузе и постменопаузе чаще страдают от вазомоторных симптомов. Для купирования вазомоторных симптомов назначается заместительная гормональная терапия, которая может усугублять течение мигрени. В данном обзоре будут подробно рассмотрены вопросы влияния перименопаузы и постменопаузы на течение мигрени, вопросы применения гормональной заместительной терапии, методы купирования и профилактики приступов у пациенток с мигренью.

1. Азимова ЮЭ, Амелин АВ, Алферова ВВ и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134

2. MacGregor EA. Menstrual and perimenopausal migraine: A narrative review. Maturitas. 2020 Dec;142:24-30. doi: 10.1016/j.maturitas.2020.07.005. Epub 2020 Jul 10.

3. Hipolito Rodrigues MA, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric. 2018 Jun;21(3):256-66. doi: 10.1080/13697137.2018.1439914. Epub 2018 Mar 9.

4. Harlow SD, Gass M, Hall JE, et al; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012 Apr;19(4):387-95. doi: 10.1097/gme.0b013e31824d8f40

5. Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during menopausal transition. Headache. 2003 May;43(5):470-8. doi: 10.1046/j.1526-4610.2003.03092.x

6. Oh K, Jung KY, Choi JY, et al. Headaches in middle-aged women during menopausal transition: a headache clinic-based study. Eur Neurol. 2012;68(2):79-83. doi: 10.1159/000336838. Epub 2012 Jul 3.

7. Ahmad SR, Rosendale N. Sex and Gender Considerations in Episodic Migraine. Curr Pain Headache Rep. 2022 Jul;26(7):505-16. doi: 10.1007/s11916-022-01052-8. Epub 2022 Jun 9.

8. Карпова МИ, Заряда АА, Долгушина ВФ идр. Мигрень уженщин: клинические итерапевтические аспекты. Журнал неврологии ипсихиатрии им.С.С.Корсакова. 2019;119(3):98-107. doi: 10.17116/jnevro201911903198

9. Cupini LM, Matteis M, Troisi E, et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995 Apr;15(2):140-4. doi: 10.1046/j.1468-2982.1995.015002140.x

10. MacGregor EA, Barnes D. Migraine in a specialist menopause clinic. Climacteric. 1999 Sep;2(3):218-23. doi: 10.3109/13697139909038065

11. Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache. 2003 Jan;43(1):27-35. doi: 10.1046/j.1526-4610.2003.03005.x

12. Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systematic review. Int J Womens Health. 2015 Aug 20;7:773-82. doi: 10.2147/IJWH.S70073

13. MacGregor EA. Classification of perimenstrual headache: clinical relevance. Curr Pain Headache Rep. 2012;16(5):452-60 doi: 10.1007/s11916-012-0282-y

14. Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache. 2016 Feb;56(2):292-305. doi: 10.1111/head.12763. Epub 2016 Jan 21.

15. Maleki N, Cheng YC, Tu Y, Locascio JJ. Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol. 2019 Jun;85(6):865-74. doi: 10.1002/ana.25476. Epub 2019 Apr 30.

16. Alebna P, Maleki N. Allostatic Load in Perimenopausal Women with Migraine. Front Neurol. 2021 Apr 22;12:649423. doi: 10.3389/fneur.2021.649423

17. Faubion SS, Ghaith S, Kling JM, et al. Migraine and sleep quality: does the association change in midlife women? Menopause. 2023 Jan 31. doi: 10.1097/GME.0000000000002149. Epub ahead of print.

18. Makita K, Inagaki M, Kitamura S, Tatsuoka Y. Changes in migraine before and after menopause in Japanese climacteric women. Cephalalgia. 2017 Oct;37(11):1088-92. doi: 10.1177/0333102416653234. Epub 2016 Jun 2.

19. Neri I, Granella F, Nappi R, et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993 Jul;17(1):31-7. doi: 10.1016/03785122(93)90121-w

20. Kim S, Lee SB, Hong YJ, et al. The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide populationbased study in South Korea. Cephalalgia. 2022 Apr;42(4-5):376-84. doi: 10.1177/03331024211044441. Epub 2021 Sep 27.

21. Carturan P, Scorcine C, Fragoso YD. Migraine in the post-menopausal period is associated with higher levels of mood disorders, disability, and more menopausal symptoms. Arq Neuropsiquiatr. 2016 Dec;74(12):9991002. doi: 10.1590/0004-282X20160153

22. Cull RE. Investigation of late-onset migraine. Scott Med J. 1995 Apr;40(2):50-2. doi: 10.1177/003693309504000205

23. MacDonald CJ, El Fatouhi D, Madika AL, et al. Association of Migraine With Incident Hypertension After Menopause: A Longitudinal Cohort Study. Neurology. 2021 Jul 6;97(1):e34e41. doi: 10.1212/WNL.0000000000011986. Epub 2021 Apr 21.

24. Mathes RW, Malone KE, Daling JR, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3116-22. doi: 10.1158/1055-9965.EPI-08-0527

25. Li CI, Mathes RW, Malone KE, et al. Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2030-4. doi: 10.1158/1055-9965.EPI-09-0291

26. Li CI, Mathes RW, Bluhm EC, et al. Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol. 2010 Feb 20;28(6):1005-10. doi: 10.1200/JCO.2009.25.0423. Epub 2010 Jan 25.

27. Phipps AI, Anderson GL, Cochrane BB, et al. Migraine history, nonsteroidal antiinflammatory drug use, and risk of postmenopausal endometrial cancer. Horm Cancer. 2012 Dec;3(5-6):240-8. doi: 10.1007/s12672012-0117-7. Epub 2012 Jul 24.

28. Nappi RE, Tiranini L, Sacco S, et al. Role of Estrogens in Menstrual Migraine. Cells. 2022 Apr 15;11(8):1355. doi: 10.3390/cells11081355

29. Rustichelli C, Bellei E, Bergamini S, et al. Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study. Cephalalgia. 2020 Oct;40(12):1355-62. doi: 10.1177/0333102420937742. Epub 2020 Jun 26.

30. Mattsson P. Serum levels of androgens and migraine in postmenopausal women. Clin Sci (Lond). 2002 Nov;103(5):487-91. doi: 10.1042/cs1030487

31. Табеева ГР. Головные боли в общеврачебной практике. Терапевтический архив. 2022;94(1):114-21. doi: 10.26442/00403660.2022.01.20

32. Farkouh ME, Greenberg BP. An evidencebased review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009 May 1;103(9):1227-37. doi: 10.1016/j.amjcard.2009.01.014

33. Curtis WD, Griffin JW. Non-steroidal antiinflammatory drug-induced gastroduodenal injury: therapeutic recommendations. Aliment Pharmacol Ther. 1991;5 Suppl 1:99-109. doi: 10.1111/j.1365-2036.1991.tb00753.x

34. Süleyman H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep. 2007 MayJun;59(3):247-58.

35. Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015 Feb;35(2):118-31. doi: 10.1177/0333102414550416. Epub 2014 Sep 22.

36. Pavlovic JM. Evaluation and management of migraine in midlife women. Menopause. 2018 Aug;25(8):927-9. doi: 10.1097/GME.0000000000001104

37. Musson DG, Birk KL, Panebianco DL, et al. Pharmacokinetics of rizatriptan in healthy elderly subjects. Int J Clin Pharmacol Ther. 2001 Oct;39(10):447-52.

38. Peck RW, Seaber EJ, Dixon RM, et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther. 1998 Mar;63(3):342-53. doi: 10.1016/S0009-9236(98)90166-7

39. Kaniecki R. Neuromodulators for migraine prevention. Headache. 2008 Apr;48(4):586-600. doi: 10.1111/j.1526-4610.2007.01040.x. Epub 2008 Jan 18.

40. Robbins MS, Lipton RB. Management of headache in the elderly. Drugs Aging. 2010 May;27(5):377-98. doi: 10.2165/11315980000000000-00000

41. Ibor JJ, Carrasco JL, Prieto R, Garcia-Calvo C; Ceres Study Group. Effectiveness and safety of venlafaxine extended release in elderly depressed patients. Arch Gerontol Geriatr. 2008 May-Jun;46(3):317-26. doi: 10.1016/j.archger.2007.05.005. Epub 2007 Jul 6.

42. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012 Jun;52(6):930-45. doi: 10.1111/j.1526-4610.2012.02185.x

43. Tepper SJ. CGRP and headache: a brief review. Neurol Sci. 2019 May;40(Suppl 1):99105. doi: 10.1007/s10072-019-03769-8

44. Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116

45. Головачева ВА, Головачева АА, Парфенов ВА и др. Когнитивно-поведенческая терапия в лечении хронической мигрени: описание клинического случая. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):7480. doi: 10.14412/2074-2711-2021-1-74-80

46. Головачева ВА. Лечение хронической мигрени и инсомнии с помощью когнитивно-поведенческой терапии. Медицинский совет. 2023;(3):68-76. doi: 10.21518/ms2023-080

47. Tiseo C, Vacca A, Felbush A, et al; European Headache Federation School of Advanced Studies (EHF-SAS). Migraine and sleep disorders: a systematic review. J Headache Pain. 2020 Oct 27;21(1):126. doi: 10.1186/s10194-020-01192-5

48. Amin FM, Aristeidou S, Baraldi C, et al; European Headache Federation School of Advanced Studies (EHF-SAS). The association between migraine and physical exercise. J Headache Pain. 2018 Sep 10;19(1):83. doi: 10.1186/s10194-018-0902-y

49. Denche-Zamorano A, Paredes-Mateos V, Pastor-Cisneros R, et al. Physical Activity Level, Depression, Anxiety, and Self-Perceived Health in Spanish Adults with Migraine: A Cross-Sectional Study. Int J Environ Res Public Health. 2022 Oct 25;19(21):13882. doi: 10.3390/ijerph192113882

50. Hodson J, Thompson J, al-Azzawi F. Headache at menopause and in hormone replacement therapy users. Climacteric. 2000 Jun;3(2):119-24. doi: 10.3109/13697130009167613

51. Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. Maturitas. 2001 Apr 20;38(2):157-63. doi: 10.1016/s03785122(00)00215-2

52. Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002 Oct;42(9):924-9. doi: 10.1046/j.15264610.2002.02215.x. Erratum in: Headache. 2003 Feb;43(2):172. Erratum in: Headache. 2003 Mar;43(3):310.

53. Misakian AL, Langer RD, Bensenor IM, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt). 2003 Dec;12(10):1027-36. doi: 10.1089/154099903322643956

54. Aegidius KL, Zwart JA, Hagen K, et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol. 2007 Jan;14(1):73-8. doi: 10.1111/j.14681331.2006.01557.x

55. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321

56. Кирьянова ЕА, Табеева ГР. Гормональная терапия менструально-ассоциированной мигрени: за и против. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):6975. doi: 10.14412/2074-2711-2022-1-69-75

57. Sahni S, Lobo-Romero A, Smith T. Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review. touchREV Endocrinol. 2021 Nov;17(2):133-7. doi: 10.17925/EE.2021.17.2.133. Epub 2021 Oct 13.

58. Артымук НВ, Тачкова ОА, Марочко ТЮ. Современные подходы к управлению менопаузой. Гинекология. 2021;23(2):137-43. doi: 10.26442/20795696.2021.1.200691